<SEC-DOCUMENT>0001193125-25-129476.txt : 20250528
<SEC-HEADER>0001193125-25-129476.hdr.sgml : 20250528
<ACCEPTANCE-DATETIME>20250528160802
ACCESSION NUMBER:		0001193125-25-129476
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250528
DATE AS OF CHANGE:		20250528

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279773
		FILM NUMBER:		25995486

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d122639d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-279773</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
December&nbsp;2, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>1,770,000 American Depositary Shares representing 885,000,000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g122639g0523011050188.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December&nbsp;2, 2024 (the
&#147;Prospectus&#148;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-279773),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on May&nbsp;28, 2025 (the &#147;May 28, 2025 Form <FONT STYLE="white-space:nowrap">6-K&#148;).</FONT> Accordingly, we have attached the
May&nbsp;28, 2025 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and supplements the
information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction
with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;KZIA.&#148; On May&nbsp;27, 2025, the last reported sale price of
the ADSs on Nasdaq was $3.74 per ADS. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page 9 of the Prospectus and the
&#147;Risk Factors&#148; in &#147;Item 3. Key <FONT STYLE="white-space:nowrap">Information-D.</FONT> Risk Factors&#148; of our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the
Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal
offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is May&nbsp;28, 2025 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">6-K</FONT></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of May, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results of Annual General Meeting </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As scheduled, Kazia Therapeutics Limited (the &#147;Company&#148;) held its Annual General Meeting (the &#147;AGM&#148;) at 10:00 a.m., Sydney
time, on May&nbsp;22, 2025, at an online venue. At the AGM, the Company&#146;s shareholders voted on one resolution with respect to the <FONT STYLE="white-space:nowrap">re-election</FONT> of Robert Apple as a director of the Company, which is listed
below and was described in more detail in the Company&#146;s Notice of Annual General Meeting and accompanying Explanatory Statement, which are available electronically on the &#147;For Investors&#148; section of the Company&#146;s website. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Resolution 1 &#150; <FONT STYLE="white-space:nowrap">Re-election</FONT> of Robert Apple as Director </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">re-election</FONT> of Robert Apple as a director of the Company was approved by the Company&#146;s shareholders. The
results of the approval were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:6pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FOR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AGAINST</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ABSTAIN</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>UNDIRECTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>VOTES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,790,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,986,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,365,965</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited</B> (Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 28&nbsp;May 2025</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g122639g0523011050188.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g122639g0523011050188.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] -4# 2(  A$! Q$!_\0
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GO:+*EK&LY#2A0&(Z$U:I/NCBEJ2TK(6BDHH&+1244 +1244 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
